USPTO serial 79449402
CONFOBODY
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- SEVERSON, JUSTIN
- Law office
- TMO LAW OFFICE 111
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CONFOBODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jessica S. Sachs
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.100 Bloomfield Hills ParkwaySuite 200Bloomfield Hills, MI 48304Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substances, namely, antibodies for stabilization of proteins, all the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); proteins for use in science; chimeric proteins to measure, test and develop compounds and ligands binding to G protein-coupled receptors (GPCRs); single-domain antibodies for scientific and laboratory use, particularly for stabilizing G protein-coupled receptors (GPCRs) in pharmacologically relevant conformations; chemical and biochemical preparations for use in screening technologies for identifying chemical starting points in drug discovery; biochemical reagents for use in structural biology and conformational analysis of membrane proteins, other than for medical or veterinary purposes; chemical substances for use in the identification and characterization of druggable conformers of G protein-coupled receptors (GPCRs), other than for medical or veterinary purposes; stabilized protein conformers for use in scientific research and drug discovery; reagents for research purposes for use in high-throughput screening assays targeting GPCRs; biochemical preparations for use in the development of universal G protein-coupled receptor stabilizers | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations for use in oncology and in the field of immunology, namely, pharmaceutical and veterinary preparations for treating immune-related diseases; pharmaceutical and veterinary preparations for the treatment of inflammatory diseases and infections and for the treatment of gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan diseases; chemical and biochemical substances for pharmaceutical and veterinary use in the nature of stabilized protein arrays, namely, small molecules and antibodies for diagnostic purposes for use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections; chemical and biochemical substances for pharmaceutical and veterinary use in the nature of stabilized protein arrays, namely, small molecules and antibodies for treatment of gastrointestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan diseases; veterinary products, namely, antibody reagents used for the detection of antigens in cells and tissue for medical purposes; veterinary products, namely, antibody reagents for therapeutic use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan diseases; veterinary products, namely, small molecules in the form of low molecular weight organic compounds; veterinary products, namely, biological preparations for use in oncology and in the field of immunology and for the treatment of inflammatory diseases and infections and for the treatment of gastrointestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological and musculo-skeletal conditions and for the treatment of orphan disease; diagnostic and therapeutic preparations based on single-domain antibodies for use in the treatment of orphan and rare diseases; pharmaceutical preparations for neurological disorders involving undruggable G protein-coupled receptor targets; biological preparations comprising stabilized G protein-coupled receptors for use in immunology and oncology; pharmaceutical preparations for use in identifying and validating novel agonists for G protein-coupled receptors; diagnostic agents for use in companion diagnostics involving G protein-coupled receptor-targeted therapies; pharmaceutical preparations for use in precision medicine targeting dynamic membrane proteins | ACTIVE | — |
| 042 | Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines; Scientific research services in the field of G protein-coupled receptor stabilization using single-domain antibodies; scientific research and development services relating to antibody-based G protein-coupled receptor stabilization and screening technologies; structural biological research laboratory services for identifying druggable conformers of G protein-coupled receptors; development of screening platforms for identifying chemical starting points in G protein-coupled receptor drug discovery; scientific research services in the field of orphan and rare diseases involving G protein-coupled receptor targets; design and development of proprietary antibody-based technologies for use in drug discovery; platform-as-a-service (PaaS) services featuring software platforms for G protein-coupled receptor conformational analysis and screening; scientific research consultancy relating to the use of stabilized G protein-coupled receptors in pharmaceutical development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 12, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 12, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 12, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 6, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 23, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 23, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 5, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 4, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 3, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| May 8, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 8, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 7, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |